Proteomics and transcriptomics reveal molecular subtypes and biomarkers of advanced cutaneous T-cell lymphoma - Takeaways - MDSpire

Proteomics and transcriptomics reveal molecular subtypes and biomarkers of advanced cutaneous T-cell lymphoma

  • By

  • Shan Zhang

  • Zhengguang Guo

  • Zhaorui Liu

  • Zhiyu Pang

  • Feng Qi

  • Haidan Sun

  • Wei Sun

  • Jie Liu

  • July 15, 2026

Share

  • 1

    Advanced cutaneous T-cell lymphomas (CTCL) include mycosis fungoides and Sézary syndrome, characterized by aggressive behavior and treatment response variability.

  • 2

    Three molecular subtypes of advanced CTCL were identified: intracellular signaling, metabolic, and extracellular matrix remodeling, each with distinct clinical phenotypes.

  • 3

    The PI3K-AKT-mTOR pathway was upregulated in the intracellular signaling subtype, with phospho-AKT levels linked to response to PI3Kδ inhibitor therapy.

  • 4

    Potential biomarkers for predicting treatment responsiveness include CTSB, GSTO1, and WDFY4, while GOLGA1 and STIP1 may indicate disease progression.

  • 5

    The study provides preliminary evidence of molecular differences in advanced CTCL, which may correlate with clinical characteristics and require further validation.

Original Source(s)

Proteomics and transcriptomics reveal molecular subtypes and biomarkers of advanced cutaneous T-cell lymphoma

  • by Shan Zhang, Zhengguang Guo, Zhaorui Liu, Zhiyu Pang, Feng Qi, Haidan Sun, Wei Sun, Jie Liu

  • July 15, 2026

Related Content

Transformation from lung adenocarcinoma to pulmonary giant cell carcinoma following targeted therapy: a case report

A hybrid ViT-L/32–MaxViT-L architecture with adaptive gated fusion for multiclass gastrointestinal disease detection and multi-method post-hoc explainability

Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis